Skip to main content
SpringerLink
Log in

Comparison of the BASDAI and the miniBASDAI in assessing disease activity in patients with ankylosing spondylitis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is the most widely used instrument for the assessment of disease activity in ankylosing spondylitis (AS). Objective. The aims to investigate whether the alternative BASDAI, here termed as the miniBASDAI [(Question (Q) 1 fatigue + Q2 spinal pain) + mean of (Q5 strength morning stiffness + Q6 duration morning stiffness)] / 3], measures disease activity more accurately in the subgroup of AS patients without peripheral manifestations. One hundred and ten patients were included in this cross-sectional study according to the modified New York criteria for AS. Clinical and biological parameters were evaluated. The disease activity was evaluated by the BASDAI. We calculated the miniBASDAI by omitting both the peripheral joints and the enthesitis questions: questions 3 and 4. Patients were dichotomized into a “P+” group if peripheral manifestations were present (at least arthritis or enthesitis) and a “P−” group, the subgroup without peripheral involvement (with either arthritis or enthesitis). Correlation of the BASDAI and miniBASDAI with other disease parameters were examined with the Spearman's rank correlation analysis. One hundred and ten patients were recruited. The percentage of patients with pure axial disease manifestation without peripheral involvement “P − group” was 42.7%. We found a similarly good correlation of the miniBASDAI with patient global, physician on disease activity, BASFI, ESR and CRP if compared to the correlation of the original BASDAI with these disease parameters, also in the group without peripheral involvement. Our study suggests that the BASDAI remains valid in assessing disease activity in AS patients with and without peripheral manifestations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Calin A (1998) Ankylosing spondylitis. In: Maddison PJ, Isenberg D, Woo P, Glass D (Eds.). Oxford textbook of rheumatology 2nd edn. (Oxford Medical Publications, Oxford University Press, USA); pp. 1058–60

  2. Khan MA (1995) HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 7:263–269

    Article  PubMed  CAS  Google Scholar 

  3. Pham T (2008) Pathophysiology of ankylosing spondylitis: what's new? Joint Bone Spine 75(6):656–660

    Article  PubMed  CAS  Google Scholar 

  4. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291

    PubMed  CAS  Google Scholar 

  5. Rostom S, Benbouaaza K, Amine B, Bahiri R, Ibn Yacoub Y, Ali Ou Alla S, Abouqal R, Hajjaj-Hassouni N (2010) Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis. Clin Rheumatol 29(7):781–788

    Article  PubMed  Google Scholar 

  6. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 38:878–882

    Article  CAS  Google Scholar 

  7. Jones SD, Calin A, Steiner A (1996) An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores. J Rheumatol 23:407

    PubMed  CAS  Google Scholar 

  8. Goie The HS, Steven MM, van der Linden SM, Cats A (1985) Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 24:242–249

    Article  PubMed  CAS  Google Scholar 

  9. Calin A, Garrett S, Whitelock H et al (1994) New approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index (BASFI). J Rheumatol 21:2281–2285

    PubMed  CAS  Google Scholar 

  10. Jenkinson TR, Mallorie PA, Whitelock H, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis: the Bath Ankylosing Spondylitis Metrology Index. J Rheumatol 21:1694–1698

    PubMed  CAS  Google Scholar 

  11. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 6;359(9313):1187–93

    Google Scholar 

  12. Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675

    Article  PubMed  CAS  Google Scholar 

  13. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727

    Article  PubMed  CAS  Google Scholar 

  14. Song IH, Rudwaleit M, Listing J, Sieper J (2009) Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 68(11):1701–1707

    Article  PubMed  CAS  Google Scholar 

  15. Carette S, Graham D, Little H, Rubenstein J, Rosen P (1983) The natural disease course of ankylosing spondylitis. Arthritis Rheum 26:186–190

    Article  PubMed  CAS  Google Scholar 

  16. Claudepierre P, Sibilia J, Roudot Thoraval F, Flipo RM, Wendling D, Goupille P et al (1998) Factors linked to disease activity in a French cohort of patients with spondyloarthropathy. J Rheumatol 25:1927–1931

    PubMed  CAS  Google Scholar 

  17. Heuft-Dorenbosch L, Van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, Van Der Tempel H, Van Der Heijde D (2004) The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis and Rheumatism (Arthritis Care & Research) 51(2):154–159

    Article  Google Scholar 

  18. Braun J, Pham T, Sieper J et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824

    Article  PubMed  CAS  Google Scholar 

  19. Braun J, Davis J, Dougados M et al (2006) First update of the International ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316–320

    Article  PubMed  CAS  Google Scholar 

  20. Pham T, Fautrel B, Dernis E et al (2007) Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patient with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74:638–646

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology, El Ayachi University Hospital, Rabat-Sale, Morocco

    Jinane Hakkou, Samira Rostom, Nawal Aissaoui, Kenza Berrada Ghezioul, Rachid Bahiri & Najia Hajjaj-Hassouni

  2. Laboratory of Biostatistical, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Rabat University Mohammed V-Souissi, Rabat, Morocco

    Redouane Abouqal & Najia Hajjaj-Hassouni

  3. Department of Rheumatology, El Ayachi University Hospital, Sale, Morocco

    Jinane Hakkou

Authors
  1. Jinane Hakkou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samira Rostom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nawal Aissaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenza Berrada Ghezioul
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachid Bahiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Redouane Abouqal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Najia Hajjaj-Hassouni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jinane Hakkou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hakkou, J., Rostom, S., Aissaoui, N. et al. Comparison of the BASDAI and the miniBASDAI in assessing disease activity in patients with ankylosing spondylitis. Clin Rheumatol 31, 441–445 (2012). https://doi.org/10.1007/s10067-011-1872-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-011-1872-5

Keywords

Search

Navigation